EGFR and non-small cell lung carcinoma: Initially, the AURA3 trial [3] demonstrated the superiority of osimertinib in comparison to platinum-based doublet chemotherapy in T790M-positive advanced NSCLC in patients progressing on first-line EGFR TKI therapy, and subsequently, the FLAURA trial [4,5] demonstrated its superiority over the earlier-generation TKIs in the first-line setting by significantly prolonging both progression-free survival (PFS) and overall survival (OS) while maintaining a tolerable safety profile.